News from Cantargia AB A wide array of domestic and global news stories on topics including politics, business, technology, religion, sports, entertainment, science, health and lifestyle.

Latest News from Cantargia AB

14:04 BST Cantargia Presented Positive Phase I Clinical Data with Lead Candidate CAN04 at ESMO

The antibody CAN04 was well tolerated and 6 mg/kg is a safe dose - Effects on biomarkers and 5 of 13 evaluable patients achieved stable...


09 Oct, 2018, 07:46 BST Cantargia Presents Clinical Data From its Ongoing CANFOUR Trial at ESMO

Cantargia AB (publ) today announced that interim results from its clinical Phase I/II trial of lead candidate CAN04 (nidanilimab) will be presented...


01 Oct, 2018, 07:44 BST Cantargia Obtains Patent in USA for the Antibody CAN03

Cantargia AB today announces that the United States Patent and Trademark Office (USPTO) has granted the company's patent application 15/501,710...


19 Sep, 2018, 17:14 BST Cantargia Publishes Prospectus in Connection with the List Change to Nasdaq Stockholm's Main Market

On 13 September 2018, Cantargia AB (publ) ("Cantargia" or the "Company") announced that Nasdaq Stockholm's Listing Committee had approved the...


19 Sep, 2018, 10:43 BST Cantargia Obtains Patent Approval for the Antibody CAN04 (nidanilimab) in Japan

Cantargia AB announce that the Japanese patent authority, JPO has formally approved the company's patent application of the antibody CAN04...


13 Sep, 2018, 17:08 BST Cantargia Has Been Approved for Listing on the Main Market of Nasdaq Stockholm

Nasdaq Stockholm's Listing Committee has approved the admission of Cantargia AB's (publ) ("Cantargia" or the "Company") shares for trading on the...


21 Aug, 2018, 07:51 BST Cantargia Publishes Half Year Report

Cantargia AB's half year report for the period January until June 2018 is now available on the company's web page...


13 Aug, 2018, 08:09 BST Cantargia Presents Update on the CANFOUR Clinical Trial and Phase IIa Preparations

- 15 patients treated and CAN04 showed a good safety profile - A few more patients to be included to establish maximum tolerated or recommended...


01 Aug, 2018, 12:16 BST Cantargia Obtains Patent Approval for the Antibody CAN04 (nidanilimab) in China

Cantargia AB announce that the Chinese patent authority, State Intellectual Property Office ("SIPO") has issued a formal approval concerning the...


13 Jul, 2018, 14:21 BST Cantargia Approved for Listing on Nasdaq Stockholm First North Premier as Part of the Process Towards Nasdaq Stockholm's Main Market

Cantargia AB ("Cantargia"), as previously announced, intends to list the company on Nasdaq Stockholm main market in 2018. As part of the ongoing...


11 Jul, 2018, 08:17 BST Cantargia Receives Intention to Grant Notification From EPO for Expanded Patent Protection in Treatment of Solid Tumours

Cantargia AB announce that the European Patent Office (EPO) has issued an Intention to grant notification for the company's divisional (second,...


26 Jun, 2018, 14:13 BST Cantargia Announces Pre-clinical Results Showing Positive Effects of CAN04 Combined With Approved Cancer Therapies

Cantargia AB today announces pre-clinical results from a study combining the antibody CAN04 (nidanilimab) and chemotherapy. In in vivo based models...


26 Jun, 2018, 07:43 BST Cantargia Obtains Two New Granted Patents in USA for Antibody-based Cancer Therapy Against IL1RAP

Cantargia AB today announces that the United States Patent and Trademark Office (USPTO) has granted two of the company's patent applications. The...


19 Jun, 2018, 14:09 BST Cantargia's Immuno-oncology Antibody CAN04 has Obtained the INN nidanilimab by WHO

Cantargia AB today announces that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) nidanilimab as the...


16 May, 2018, 11:14 BST Cantargia's Immuno-oncology Project CAN04 Shows Promise in Additional Cancer Forms

Cantargia AB today announces that the company has generated novel data showing high levels of interleukin-1 receptor accessory protein (IL1RAP) in...


15 May, 2018, 07:53 BST Cantargia Publishes Interim Report for First Quarter 2018

Cantargia AB's ("Cantargia") interim report for the first quarter of 2018 is now available on the company's web page...


04 May, 2018, 07:39 BST Cantargia's European Patents for Both Leukemia and Solid Tumours Remain Valid After Appeal Period Ends

Cantargia AB ("Cantargia") today announces that the company's European patents covering antibody treatment of leukemia as well as solid tumours...


03 May, 2018, 15:46 BST Cantargia Receives Patent Approval in Canada and Broadens Protection with Respect to Hematological Cancer

Cantargia AB ("Cantargia") today announces that the Canadian patent office ("CIPO") has formally granted the company's application for a patent...


16 Apr, 2018, 14:06 BST Cantargia Presents Anti-metastatic Effect of IL1RAP Blocking Antibody at AACR

Today, Cantargia AB presents novel data using antibody therapy against interleukin 1 receptor accessory protein (IL1RAP) at the American...


15 Mar, 2018, 07:40 GMT Cantargia Presents New Data at AACR on Inhibition of Metastasis by Antibodies Against IL1RAP

Cantargia AB ("Cantargia") today announces that data on the anti-metastatic properties of an antibody against interleukin 1 receptor accessory...


06 Mar, 2018, 14:38 GMT Cantargia: Antibody Against ILRAP Reduce Metastases in Experimental Cancer Model

Cantargia AB ("Cantargia") today announces that antibody blockade of IL1RAP signalling, reduce metastases in an experimental cancer model. The...


27 Feb, 2018, 07:38 GMT Cantargia Receives Notice of Allowance From USPTO for Expanded Protection in Treatment of Leukemia

Cantargia AB ("Cantargia") has been notified that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US...


23 Jan, 2018, 13:18 GMT Cantargia's European Patent for Hematological Cancers Remains in Force

The opposition proceedings at the European Patent Office ("EPO") concerning Cantargia AB's ("Cantargia") patent for treatment of hematological...


22 Jan, 2018, 10:19 GMT European Patent Office Cancels Oral Opposition Proceedings Concerning Cantargia's Patent for Hematological Cancers

In the ongoing opposition proceedings at the European Patent Office ("EPO") concerning Cantargia AB's ("Cantargia") patent for antibody treatment...


19 Jan, 2018, 10:43 GMT Cantargia's European Patent for Solid Tumours Remains in Force

The opposition proceedings at the European Patent Office ("EPO") concerning Cantargia AB's ("Cantargia") patent for treatment of solid tumours...